Revolutionary Pediatric Cancer & Blood Disorder Research
Rapidly Developing Treatments from Lab to Bedside
Ranked as one of the top programs in the country by U.S. News and World Report for expertise in treating cancer and blood disorders, University Hospitals Rainbow Babies & Children’s Hospital provides advanced care for pediatric patients ranging from infants to young adults.
A crucial part of our mission at UH Rainbow is to make significant scientific discoveries about blood disorders and cancers and integrate them into our patients’ care. Our research scientists collaborate with clinicians at the point of care. Together, we find new therapies, drugs and medical devices that will change the way cancer and blood disorders are treated and bring them rapidly to our patients, including proton therapy and stem cell transplants.
Our pediatric cancer and blood disorder team works closely with University Hospitals’ own Harrington Discovery Institute, an international initiative dedicated to physician-scientists. Our scholars strive to transform breakthrough discoveries into new medicines.
Nationally Renowned Scientific Institute
The Angie Fowler Adolescent and Young Adult Institute has a rigorous research program with a national reputation for scientific and translational innovation in pediatric hematology, oncology and immunotherapy. As a full member of the Children’s Oncology Group (COG) and the Therapeutic Advances in Childhood Leukemia (TACL) Foundation, Angie’s Institute fuels innovative research and clinical trials which lead to ground breaking treatments and gives hope to adolescent and young adult cancer and blood disorder patients.
Part of an Elite Group of Cancer Treatment Centers
University Hospitals Rainbow Babies & Children’s partners with and is the primary pediatric affiliate to the prestigious Case Comprehensive Cancer Center (CCCC), part of Case Western Reserve University School of Medicine. Through this relationship, we are linked with other medical institutions in a stronger and more unified effort to understand the causes and progression of cancer. We use this understanding to develop new treatments for infants, children, adolescents and young adults with cancer and improve patient outcomes.